Franco-Nevada Corporation (FNV)

CTI BioPharma Stock Forecast

Stock Price Forecast

The 7 analysts that cover CTI BioPharma stock have a consensus rating of "Buy" and an average price target of $169, which forecasts a -1.51% decrease in the stock price over the next year. The lowest target is $137 and the highest is $210.

Price Target: $169 (-1.51%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$137	$169	$169	$210
Change	-20.16%	-1.51%	-1.51%	+22.38%

* Price targets were last updated on Jul 3, 2025.

Analyst Ratings

The average analyst rating for CTI BioPharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Mar '25	Apr '25	May '25	Jun '25	Jul '25	Aug '25
Strong Buy	3	3	3	3	3	3
Buy	1	1	1	1	1	1
Hold	4	4	4	4	4	4
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	8	8	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Daniel Major UBS	UBS	Strong Buy Maintains $205 → $210	Strong Buy	Maintains	$205 → $210	+22.38%	Jul 3, 2025
Heiko Ihle HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $180 → $195	Strong Buy	Maintains	$180 → $195	+13.64%	May 28, 2025
Tanya Jakusconek Scotiabank	Scotiabank	Hold Maintains $165 → $169	Hold	Maintains	$165 → $169	-1.51%	May 12, 2025
Tanya Jakusconek Scotiabank	Scotiabank	Hold Maintains $150 → $165	Hold	Maintains	$150 → $165	-3.84%	Apr 14, 2025
Daniel Major UBS	UBS	Strong Buy Maintains $170 → $190	Strong Buy	Maintains	$170 → $190	+10.73%	Apr 11, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

1.58B

Increased by 42.99%

from 1.10B

Revenue Next Year

1.85B

Increased by 17.45%

from 1.58B

EPS This Year

4.17

Increased by 45.26%

from 2.87

EPS Next Year

5.20

Increased by 24.81%

from 4.17

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	1.02B	1.30B	1.31B	1.22B	1.10B	1.58B	1.85B	1.89B
Revenue Growth	20.86%	27.55%	1.23%	-7.36%	-9.43%	42.99%	17.45%	2.27%
EPS	1.71	3.83	3.65	-2.43	2.87	4.17	5.20	5.09
EPS Growth	-6.56%	123.98%	-4.70%	-	-	45.26%	24.81%	-2.09%
Forward PE	-	-	-	-	-	41.16	32.98	33.69
No. Analysts	-	-	-	-	-	15	13	4

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	1.8B	2.3B	2.5B
Avg	1.6B	1.9B	1.9B
Low	1.2B	1.6B	1.4B

Revenue Growth

Revenue Growth	2025	2026	2027
High	61.0%	47.3%	33.3%
Avg	43.0%	17.4%	2.3%
Low	9.9%	-0.4%	-23.4%

EPS Forecast

EPS	2025	2026	2027
High	4.67	6.03	5.65
Avg	4.17	5.20	5.09
Low	3.56	4.65	4.76

EPS Growth

EPS Growth	2025	2026	2027
High	62.8%	44.8%	8.6%
Avg	45.3%	24.8%	-2.1%
Low	24.0%	11.4%	-8.4%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.